{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:13:24Z","timestamp":1788909204729,"version":"build-2803163510"},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.rdc.2005.12.002","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T10:09:23Z","timestamp":1168423763000},"page":"157-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Advances in the Treatment of Small Vessel Vasculitis"],"prefix":"10.1016","volume":"32","author":[{"given":"Eamonn S.","family":"Molloy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Langford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2005.12.002_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/ar771","article-title":"Wegener's granulomatosis: current and upcoming therapies","volume":"5","author":"Langford","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2005.12.002_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)","volume":"34","author":"Walton","year":"1958","journal-title":"BMJ"},{"key":"10.1016\/j.rdc.2005.12.002_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","article-title":"Wegener's granulomatosis: studies in eighteen patients and a review of the literature","volume":"52","author":"Fauci","year":"1973","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rdc.2005.12.002_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/art.1780370622","article-title":"Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis","volume":"37","author":"Reinhold-Keller","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0002-9343(90)90367-M","article-title":"Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide","volume":"89","author":"Hoffman","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib8","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib9","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/ndt\/16.10.2018","article-title":"The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review","volume":"16","author":"de Groot","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.rdc.2005.12.002_bib10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/rheumatology\/keh609","article-title":"Translational research in autoimmunity: aims of therapy in vasculitis","volume":"44","author":"Watts","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2005.12.002_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib12","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/art.1780380505","article-title":"An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone","volume":"38","author":"Sneller","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib13","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/1529-0131(200008)43:8<1836::AID-ANR20>3.0.CO;2-R","article-title":"Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis","volume":"43","author":"Langford","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib14","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/art.1780351113","article-title":"The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate","volume":"35","author":"Hoffman","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib15","first-page":"492","article-title":"Induction of remission in Wegener's granulomatosis with low dose methotrexate","volume":"25","author":"de Groot","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2005.12.002_bib16","first-page":"1134","article-title":"Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice","volume":"26","author":"Stone","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2005.12.002_bib17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0002-9343(03)00077-9","article-title":"Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse","volume":"114","author":"Langford","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib18","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/1529-0131(199912)42:12<2666::AID-ANR24>3.0.CO;2-E","article-title":"A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance","volume":"42","author":"Langford","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/art.10459","article-title":"High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate","volume":"47","author":"Reinhold-Keller","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib21","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1681\/ASN.V1091965","article-title":"Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement","volume":"10","author":"Nowack","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2005.12.002_bib22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/art.20240","article-title":"Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis","volume":"51","author":"Langford","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ndt\/17.5.923","article-title":"A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis","volume":"17","author":"Maes","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.rdc.2005.12.002_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2005.12.002_bib25","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(05)75088-1","article-title":"Leflunomide for active rheumatoid arthritis","volume":"353","author":"Bruyn","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2005.12.002_bib26","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/rheumatology\/keg120","article-title":"Leflunomide induced vasculitis\u2014a dose-response relationship","volume":"42","author":"Chan","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2005.12.002_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/rheumatology\/keh009","article-title":"Maintenance of remission with leflunomide in Wegener's granulomatosis","volume":"43","author":"Metzler","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2005.12.002_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/01.ASN.0000048716.42876.14","article-title":"15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six month open-label trial to evaluate safety and efficacy","volume":"14","author":"Birck","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2005.12.002_bib29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"},{"key":"10.1016\/j.rdc.2005.12.002_bib30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0049-0172(86)90020-X","article-title":"Cytotoxic drugs: their clinical application to the rheumatic diseases","volume":"15","author":"Clements","year":"1986","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib31","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/13543784.10.7.1279","article-title":"Novel therapies in vasculitis","volume":"10","author":"Thomas-Golbanov","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.rdc.2005.12.002_bib32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/978-1-4757-9182-2_85","article-title":"Cyclosporin A therapy for Wegener's granulomatosis","volume":"336","author":"Allen","year":"1993","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.rdc.2005.12.002_bib33","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/ndt\/13.8.2074","article-title":"Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis","volume":"13","author":"Haubitz","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.rdc.2005.12.002_bib34","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1523-1755.2004.00534.x","article-title":"Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients","volume":"65","author":"Schmitt","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.rdc.2005.12.002_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0025-6196(12)65279-3","article-title":"Wegener's granulomatosis: observations on treatment with antimicrobial agents","volume":"60","author":"DeRemee","year":"1985","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.rdc.2005.12.002_bib36","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1001\/archinte.1988.00380100131030","article-title":"Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis","volume":"148","author":"Israel","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib37","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1001\/archinte.1991.00400080133026","article-title":"Treatment of Wegener's granulomatosis with sulfamethoxazole-trimethoprim","volume":"151","author":"Valeriano-Marcet","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.qjmed.a030133","article-title":"Response to trimethoprim\/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease","volume":"89","author":"Reinhold-Keller","year":"1996","journal-title":"QJM"},{"key":"10.1016\/j.rdc.2005.12.002_bib39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group","volume":"335","author":"Stegeman","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib40","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.ajkd.2003.08.015","article-title":"Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis","volume":"42","author":"Klemmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rdc.2005.12.002_bib41","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1526-0968.2004.00131.x","article-title":"Efficacy of granulocytapheresis and leukocytapheresis for the treatment of microscopic polyangiitis","volume":"8","author":"Hasegawa","year":"2004","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.rdc.2005.12.002_bib42","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.1780391020","article-title":"Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis","volume":"39","author":"Langford","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0022-3476(05)83482-1","article-title":"Wegener granulomatosis in children and adolescents: clinical presentation and outcome","volume":"122","author":"Rottem","year":"1993","journal-title":"J Pediatr"},{"key":"10.1016\/j.rdc.2005.12.002_bib44","first-page":"1017","article-title":"Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional corticosteroids and dilation","volume":"30","author":"Hoffman","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2005.12.002_bib45","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1034\/j.1600-0463.2001.d01-146.x","article-title":"Tumour necrosis factor-alpha (TNF), lymphotoxin and TNF receptor levels in serum from patients with Wegener's granulomatosis","volume":"109","author":"Jonasdottir","year":"2001","journal-title":"APMIS"},{"key":"10.1016\/j.rdc.2005.12.002_bib46","first-page":"666","article-title":"Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis","volume":"24","author":"Nassonov","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2005.12.002_bib47","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.4049\/jimmunol.160.7.3602","article-title":"Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10","volume":"160","author":"Ludviksson","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.rdc.2005.12.002_bib48","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/ki.1993.98","article-title":"In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis","volume":"43","author":"Noronha","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.rdc.2005.12.002_bib49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","article-title":"The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection","volume":"56","author":"Kindler","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.rdc.2005.12.002_bib50","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","article-title":"Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis","volume":"15","author":"Booth","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2005.12.002_bib51","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","article-title":"Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients","volume":"41","author":"Bartolucci","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2005.12.002_bib52","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","article-title":"Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis","volume":"41","author":"Lamprecht","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2005.12.002_bib53","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","article-title":"Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib54","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/ard.61.6.559","article-title":"Safety and efficacy of TNFalpha blockade in relapsing vasculitis","volume":"61","author":"Booth","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2005.12.002_bib55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib56","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rdc.2005.12.002_bib57","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib58","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib59","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rdc.2005.12.002_bib60","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rdc.2005.12.002_bib61","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.rdc.2005.12.002_bib62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00000441-200302000-00005","article-title":"New indications for treatment of chronic inflammation by TNF-alpha blockade","volume":"325","author":"Reimold","year":"2003","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.rdc.2005.12.002_bib63","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","article-title":"Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway","volume":"121","author":"Lugering","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rdc.2005.12.002_bib64","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.rdc.2005.12.002_bib65","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/bst0250705","article-title":"Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma","volume":"25","author":"Anderson","year":"1997","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.rdc.2005.12.002_bib66","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib67","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1681\/ASN.V1371977","article-title":"ANCA are pathogenic\u2014oh yes they are!","volume":"13","author":"Falk","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2005.12.002_bib68","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1568-9972(01)00008-8","article-title":"New insights into the pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"1","author":"Kallenberg","year":"2002","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rdc.2005.12.002_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.20717","article-title":"Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment?","volume":"52","author":"Sneller","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib70","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib71","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","article-title":"Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab","volume":"257","author":"Eriksson","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib72","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib73","first-page":"175","article-title":"The kidney in periarteritis nodosa","volume":"17","author":"Davson","year":"1948","journal-title":"Q J Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib74","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib75","first-page":"467","article-title":"Microscopic polyarteritis: presentation, pathology and prognosis","volume":"56","author":"Savage","year":"1985","journal-title":"Q J Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib76","first-page":"221","article-title":"Polyarteritis and the kidney","volume":"62","author":"Adu","year":"1987","journal-title":"Q J Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib77","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/pgmj.65.766.515","article-title":"Microscopic polyarteritis: clinical features and treatment","volume":"65","author":"Rodgers","year":"1989","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.rdc.2005.12.002_bib78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1681\/ASN.V7123","article-title":"Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis","volume":"7","author":"Hogan","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2005.12.002_bib79","doi-asserted-by":"crossref","first-page":"49","DOI":"10.7326\/0003-4819-129-1-199807010-00012","article-title":"Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity","volume":"129","author":"Langford","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib80","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1681\/ASN.V7133","article-title":"Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis","volume":"7","author":"Nachman","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2005.12.002_bib81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00002281-199305010-00003","article-title":"Wegener's granulomatosis","volume":"5","author":"Hoffman","year":"1993","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2005.12.002_bib82","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A","article-title":"Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients","volume":"44","author":"Gayraud","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2005.12.002_bib83","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1081-1206(10)61714-0","article-title":"Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin","volume":"92","author":"Tsurikisawa","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rdc.2005.12.002_bib84","first-page":"S52","article-title":"Churg-Strauss syndrome\u2014successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment","volume":"22","author":"Metzler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2005.12.002_bib85","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-129-5-199809010-00004","article-title":"Interferon-alpha treatment of four patients with the Churg-Strauss syndrome","volume":"129","author":"Tatsis","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2005.12.002_bib86","first-page":"136","article-title":"Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement","volume":"137","author":"Termeer","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.rdc.2005.12.002_bib87","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1055\/s-2003-40284","article-title":"Interferon-alpha treatment of the Churg-Strauss syndrome","volume":"128","author":"Reissig","year":"2003","journal-title":"Dtsch Med Wochenschr"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X05000980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X05000980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:02:59Z","timestamp":1760180579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X05000980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0889857X05000980"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2005.12.002","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the Treatment of Small Vessel Vasculitis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2005.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}